AbbVie Enters into a Collaboration Agreement with BigHat Biosciences to Discover and Develop Therapeutic Antibodies
Shots:
- Both AbbVie and BigHat Biosciences have agreed to sign a collaboration agreement to discover and develop a futuristic approach to antibody treatment in the fields of Oncology and Neuroscience
- The collaboration will integrate BigHat’s Milliner platform, a combination of machine learning technologies & high-speed wet lab, along with AbbVie’s expertise in Oncology and Neuroscience to develop antibodies for multiple therapeutic targets
- As per the terms of agreement, BigHat will receive an up front payment of $30M & is also eligible to receive an aggregate of up to ~$325M in R&D and commercial milestones, plus tiered royalties
Ref: AbbVie | Image: AbbVie
Related News:- AbbVie to Acquire ImmunoGen for $10.1B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
